May 20, 2014 CardiAQ™ Valve Technologies reports Successful First-in-Human Trans-Apical implantation of its Second Generation Transcatheter Mitral Valve. For the 50% of patients suffering from severe, symptomatic Mitral Regurgitation who are denied surgery due to procedural risk, Transcatheter Mitral Valve Implantationmay offer new hope for treatment. With its latest advancement, CardiAQ is now the only company in the TMVI space to have demonstrated procedural success with both Trans-Femoral and Trans-Apical Delivery Systems.

Press Release